Abstract: The rapid development of immunotherapy has exceeded that of standard treatment modes, which include surgery, radiotherapy, chemotherapy, and targeted therapy. Immunotherapy is more durable and less toxic than traditional cancer therapies. Moreover, immune checkpoint therapy is an important component of immunotherapy and has been evaluated in preclinical and clinical trials and proven to exhibit broad prospects. However, its clinical benefits are limited to a small subset of patients with a subset of tumor types. Therefore, reasonable comprehensive therapeutic strategies are needed to overcome this limitation. Gene targeted therapy, radiotherapy, chemotherapy, and tumor vaccine affect the immune system through different mechanisms, and these could provide theoretical bases for comprehensive treatments. In this review, immune checkpoint therapy and its potential comprehensive therapies with other cancer treatments are introduced.